These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19959417)

  • 1. HIV resistance to raltegravir.
    Clavel F
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):47-54. PubMed ID: 19959417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
    Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
    J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistance to integrase inhibitors].
    Garrido C; de Mendoza C; Soriano V
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():40-6. PubMed ID: 19572425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
    Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
    AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
    Cavaco-Silva J; Abecasis A; Miranda AC; Poças J; Narciso J; Águas MJ; Maltez F; Almeida I; Germano I; Diniz A; Gonçalves Mde F; Gomes P; Cunha C; Camacho RJ;
    PLoS One; 2014; 9(3):e92747. PubMed ID: 24681625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
    Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
    J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
    Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR
    AIDS; 2011 Mar; 25(5):665-9. PubMed ID: 21326075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
    Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
    Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
    PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
    Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
    Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.